Mycophenolic acid

产品说明书

Print
Chemical Structure| 24280-93-1 同义名 : Mycophenolate;MPA;Mycophenolic acid, Mycophenolate mofetil, Cellcept, Myfortic, RS-61443;NSC 129185;RS-61443
CAS号 : 24280-93-1
货号 : A399663
分子式 : C17H20O6
纯度 : 99+%
分子量 : 320.34
MDL号 : MFCD00036814
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(327.78 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • Dehydrogenase
描述 Mycophenolic acid (MPA) is an immunosuppressant requiring therapeutic drug monitoring. It is commonly prescribed in adult kidney transplant recipients for preventing graft rejection[3]. Mycophenolic acid, the active metabolite of mycophenolate mofetil, is administered with cyclosporine and oral steroids to prevent acute rejection after renal transplant. Total body weight, time after transplant, and mycophenolate mofetil dosage according to body weight affect mycophenolic acid pharmacokinetics[4]. Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARgamma agonist[5]. Mycophenolic acid (MPA), a reversible inhibitor of inosine 5''-monophosphate dehydrogenase (IMPDH), selectively inhibits T- and B-cell proliferation. MPA exposure correlates inversely with the risk of acute rejection[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.12mL

0.62mL

0.31mL

15.61mL

3.12mL

1.56mL

31.22mL

6.24mL

3.12mL
参考文献

[1]Sintchak MD, Fleming MA, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 1996 Jun 14;85(6):921-30.

[2]Eugui EM, Almquist SJ, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991 Feb;33(2):161-73.

[3]Kiang TKL, Ensom MHH. Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients. Clin Pharmacokinet. 2019 Dec;58(12):1533-1552

[4]Nazemian F, Mohammadpur AH, Abtahi B, Naghibi M. Pharmacokinetics of mycophenolic acid during the early period after renal transplant. Exp Clin Transplant. 2007 Dec;5(2):658-63

[5]Batovska DI, Kim DH, Mitsuhashi S, Cho YS, Kwon HJ, Ubukata M. Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. Biosci Biotechnol Biochem. 2008 Oct;72(10):2623-31

[6]Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc. 2007 Jan-Feb;39(1):88-93